CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held in Orlando, FL from December 7-10, 2019.
Trials in Progress Poster Details:
Presentation Title: Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Session Name: 311. Disorders of Platelet Number or Function: Poster I
Presenter: Santiago Arroyo, M.D., Ph.D.
Date: Saturday, December 7, 2019
Presentation Time: 5:30 pm - 7:30 pm ET
Location: Orange County Convention Center, Hall B
A copy of the presentation materials can be accessed on the Publications section of the Momenta website once the presentation concludes.
About M254, Hypersialylated Immunoglobulin G
M254 is a hypersialylated human immunoglobulin G (hsIgG), engineered with significantly enhanced tetra-sialylation. In preclinical studies of ITP and other inflammatory diseases, M254 has shown an increase in potency of up to ten times that of conventional IVIg. IVIg has been used for more than 30 years for the treatment of a variety of acute and chronic autoimmune and systemic inflammatory diseases. We believe this product has the potential to be developed as a high-potency alternative to IVIg.
About Momenta
Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio. The company is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
The Company’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Forward-Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the timing of our regulatory filings for clinical development and marketing approval; the timing of regulatory approval and launch of our product candidates; development design, timelines and strategies; the Company’s ability to meet its development and strategic goals; hypotheses regarding certain actions and effects of our product candidates; market potential and revenue of our products and product candidates, design, timing and goals of clinical trials and the availability, timing and announcement of data and results; the use, efficacy, safety, potency, tolerability, convenience, dosing and commercial potential and reception of our product candidates. Forward-looking statements may be identified by words such as "believe," "continue," “plan to”, "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Patty Eisenhaur
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall
1-781-235-3060
momenta@macbiocom.com